Abstract
Persistent pulmonary hypertension of the newborn (PPHN) is a serious and potentially fatal condition, characterized by hypoxemia due to increased pulmonary vascular resistance (PVR) with resultant shunting of pulmonary blood to the systemic circulation. Inhaled nitric oxide (iNO) has been considered a revolutionary treatment of PPHN. Data show that the use of iNO has reduced the need of ECMO in neonates with severe PPHN, while in moderate PPHN, iNO administration has been associated with a significant decrease in ventilatory support and prevented progression to severe PPHN.
Not all neonates respond to iNO therapy though, and phosphodiesterase (PDE) inhibitors with their potent vasodilator properties have evolved as an alternative therapy or as an adjunct to the treatment of PPHN with iNO. There are ten families of PDE isoenzymes. PDE 5 is particularly prevalent in vascular smooth muscle (VSM) and PDE 5 inhibitors, such as sildenafil, have been used in clinical practice.
This review provides a comprehensive account of existing data in the literature, from animal and clinical studies, on the use of sildenafil for the treatment of PPHN. Sildenafil may also have a role as a single mode of therapy, since in resource-limited settings the cost of iNO is a serious concern.
Keywords: Persistent pulmonary hypertension of newborn, sildenafil, hypoxemia, pulmonary vascular resistance (PVR), pulmonary blood, systemic circulation, Inhaled nitric oxide (iNO), phosphodiesterase (PDE) inhibitors, vasodilator, vascular smooth muscle (VSM)
Current Pharmaceutical Design
Title:The use of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Review of the Literature
Volume: 18 Issue: 21
Author(s): Nicoletta Iacovidou, Aggeliki Syggelou, Vassilios Fanos and Theodoros Xanthos
Affiliation:
Keywords: Persistent pulmonary hypertension of newborn, sildenafil, hypoxemia, pulmonary vascular resistance (PVR), pulmonary blood, systemic circulation, Inhaled nitric oxide (iNO), phosphodiesterase (PDE) inhibitors, vasodilator, vascular smooth muscle (VSM)
Abstract: Persistent pulmonary hypertension of the newborn (PPHN) is a serious and potentially fatal condition, characterized by hypoxemia due to increased pulmonary vascular resistance (PVR) with resultant shunting of pulmonary blood to the systemic circulation. Inhaled nitric oxide (iNO) has been considered a revolutionary treatment of PPHN. Data show that the use of iNO has reduced the need of ECMO in neonates with severe PPHN, while in moderate PPHN, iNO administration has been associated with a significant decrease in ventilatory support and prevented progression to severe PPHN.
Not all neonates respond to iNO therapy though, and phosphodiesterase (PDE) inhibitors with their potent vasodilator properties have evolved as an alternative therapy or as an adjunct to the treatment of PPHN with iNO. There are ten families of PDE isoenzymes. PDE 5 is particularly prevalent in vascular smooth muscle (VSM) and PDE 5 inhibitors, such as sildenafil, have been used in clinical practice.
This review provides a comprehensive account of existing data in the literature, from animal and clinical studies, on the use of sildenafil for the treatment of PPHN. Sildenafil may also have a role as a single mode of therapy, since in resource-limited settings the cost of iNO is a serious concern.
Export Options
About this article
Cite this article as:
Iacovidou Nicoletta, Syggelou Aggeliki, Fanos Vassilios and Xanthos Theodoros, The use of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Review of the Literature, Current Pharmaceutical Design 2012; 18 (21) . https://dx.doi.org/10.2174/1381612811209023034
DOI https://dx.doi.org/10.2174/1381612811209023034 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Dysfunction in Hypertensive Disorders
Current Hypertension Reviews Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research ACE Inhibition of Plant Alkaloids Targeted Approach for Selective Inhibition
Mini-Reviews in Organic Chemistry Effects of Perfluorocarbon Dodecafluoropentane (NVX-108) on Cerebral Microvasculature in the Healthy Rat
Current Drug Discovery Technologies Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Study of Hypolipidemic and Antioxidant Activities of Anvillea radiata Coss & Durieu in Diabetic Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Diagnosis, Treatment, and New Developments in Preeclampsia
Current Women`s Health Reviews Synthesis, Characterization and Physico-chemical Properties of New 2-(4- Arylpiperazine-1-yl)-1-(3-methylbenzofuran-2-yl)ethanoles as Potential Antihypertensive Agents
Current Organic Chemistry Molecular Mechanisms of Renal Blood Flow Autoregulation
Current Vascular Pharmacology Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions
Current Medicinal Chemistry Coumarin and Derivates as Lipid Lowering Agents
Current Topics in Medicinal Chemistry Inflammatory Biomarkers in Chronic Kidney Disease: A Review
Recent Patents on Biomarkers Polypeptide Toxins from Animal Venoms
Recent Patents on DNA & Gene Sequences Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Stress and the α7 Nicotinic Acetylcholine Receptor
Current Drug Targets Synthesis of Novel 3(N,N-dialkylamino)alkyl/phenyl Substituted Thieno [2,3-d]pyrimidinones as H1-Anti-Histaminic and Antimicrobial Agents
Current Bioactive Compounds The Anti-fibrotic Hormone Relaxin is not Reno-protective, Despite Being Active, in an Experimental Model of Type 1 Diabetes
Protein & Peptide Letters Mechanisms of Renal Microvascular Dysfunction in Type 1 Diabetes: Potential Contribution to End Organ Damage
Current Vascular Pharmacology Nocturnal Hypertension and Chronic Kidney Disease
Current Hypertension Reviews Independent Relationship of Osteocalcin Circulating Levels with Obesity, Type 2 Diabetes, Hypertension, and HDL Cholesterol
Endocrine, Metabolic & Immune Disorders - Drug Targets